Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH100 SAD Study in Healthy Volunteers
NCT04335045Phase 1Completed
- Sponsor
- Phloronol
- Start
- Sep 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PH100 in metabolic syndrome, type 2 diabetes mellitus (T2DM) and diabetes complications (12 arms), sponsored by Phloronol. Primary endpoints: Incidence of treatment emergent adverse events, Hematology parameters (Hematocrit, Hemoglobin, Erythrocytes, Leukocytes, etc.) and 4 more. Started Sep 2013; status: completed.
02
Drugs
PH100
03
Conditions
metabolic syndrometype 2 diabetes mellitus (T2DM)diabetes complications
Beyond the preview
Go deeper on NCT04335045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335045.